Pharmaceutical giant Pfizer Inc. (PFE) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.
Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.
The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org